Estimated reading time: 5 minutes
GLP-1 medications have become increasingly popular treatments for both type 2 diabetes and weight loss. These drugs have shown great promise in managing blood sugar levels and helping with weight loss. Unfortunately, one significant hurdle remains - their high cost. For people with limited financial resources, the rising prices of these medications can be too much. People are raising concerns about accessibility and equity. What are the barriers around access to GLP-1 medications? Here is an overview from PatientsLikeMe.
Rising Costs
In recent years, the cost of GLP-1 medications has risen a lot. Wegovy, a medication specifically approved for chronic weight management, has a list price of around $1,350 for a 28-day supply. Without insurance, this can add up to more than $16,000 per year. However, many patients find themselves paying even more than the list price because of pharmacy markups. For some, the monthly cost can get as high as $2,000. This is especially true for people paying entirely out of pocket.
The increasing demand for GLP-1 medications, especially for weight loss, has driven these costs even higher. When Wegovy was first approved by the FDA in 2021, it was a breakthrough in chronic weight management. Very quickly demand outpaced supply. In March 2024, it was also approved to help prevent heart attacks and strokes in adults with cardiovascular conditions. This on increased demand. Despite its popularity and life-changing effects, many people are finding the costs too steep to sustain long-term use.
Insurance Coverage Varies
A big part in determining how much someone will pay for GLP-1 medications is their insurance. Insurance plans vary widely in how they handle weight-loss medications. For instance, Medicare, which provides healthcare coverage for millions of Americans, does not cover medications prescribed solely for weight loss. They do not view them as not medically necessary. However, if a medication like Wegovy is prescribed to prevent a life-threatening condition such as a heart attack, it may be covered.
Private insurance plans are also inconsistent! Some employer plans may cover these medications, but others do not. Even when insurance does cover Wegovy or similar drugs, patients often must meet strict eligibility criteria. Certain Medicaid programs, like those in states like California and Pennsylvania, have started to offer coverage for Wegovy. This is rare however, and certainly not the rule. Medicaid policies continue to change, and coverage is not guaranteed nationwide.
A Lack of Alternatives
Another challenge with GLP-1 medications is the lack of generic alternatives. Since Wegovy and similar drugs like Ozempic are still under patent protection, no lower-cost versions are available. This means patients have to pay the high prices set by manufacturers. With patent protections lasting 20 years, it may be quite some time before affordable generics become available. While some GLP-1 medications like Ozempic and Rybelsus, which are approved for type 2 diabetes, are available at slightly lower doses, they are not FDA-approved for weight management. This limits options for patients seeking cost-effective alternatives specifically for weight loss.
The High Costs for Low-Income Patients
For low-income individuals, the financial burden of GLP-1 medications can be overwhelming. Even with insurance, some people may still need to cover high out-of-pocket costs, which can range from several hundred to over a thousand dollars each month. Many people living paycheck to paycheck simply cannot afford to take these medications. That is even if they desperately need them for weight loss or diabetes. A recent survey showed the difference in how much patients are willing to pay for these drugs, based on their income levels. Nearly 60% of people earning more than $250,000 annually said they would be willing to spend more than $300 per month out of pocket. In contrast, 64% of people earning less than $75,000 per year said they could only afford $50 or less per month.
Programs and Savings Options
Fortunately, there are ways to reduce the financial burden! For those with commercial insurance, programs like the Wegovy Savings Card can significantly lower costs. Qualified patients may pay as little as $0 for a 28-day supply for up to 13 months, depending on their coverage. Those without commercial insurance or whose insurance does not cover Wegovy may still save up to $500 per month through manufacturer discount programs. There are also tools that can offer coupons to help patients save money on their prescriptions.
What It Means for the Future
The rising costs of GLP-1 medications pose significant challenges for many people, particularly those from low-income backgrounds. As demand continues to grow, prices are unlikely to go down unless more affordable options become available, or insurance companies start to cover these medications. For patients struggling to afford these drugs, it is important to explore every available option! This includes savings programs, insurance appeals, and medication alternatives. We will need changes to make these medications more accessible to everyone, regardless of income level.
Ultimately, while Wegovy and Ozempic offer hope to millions of people managing diabetes and obesity, their high costs also limit access for those who need them. Without policy changes or the introduction of lower-cost generics, many will continue to face difficult decisions about their health and finances.